오스코텍

039200KOSDAQ

59.0 / 100

Reference Date: 2026-10-23

Financial Score23.5 / 40

News Sentiment12.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Rose 8.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Oskotech is a research-focused biopharmaceutical company specializing in new drug development, functional materials, and dental bone grafts. It is currently conducting clinical trials for two synthetic drug candidates and holds a targeted anti-cancer drug approved by the US FDA. Major revenue streams come from technology transfer milestones and royalty income.

Number of Employees

57people

Average Salary

61.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

27.38Industry Average 15.001.5Point

1.8x industry avg (risky)

PBR

7.67Industry Average 1.200.0Point

6.4x industry avg (risky)

ROE

34.08Industry Average 8.007.0Point

4.3x industry avg (excellent)

Debt Ratio

2.16Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲390.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲1048.3% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (27%)

Current 37,450Won52-week high 62,00052-week low 28,000

1-month return5.0Point

1m +8.39% (rising)

Volume trend5.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주주명부폐쇄기간또는기준일설정2026-10-06
Neutral주주총회소집결의 (임시주주총회)2026-10-06